Oclacitinib

Oclacitinib

CAT N°: 18722
Price:

From 55.00 46.75

Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).{30396} It is selective for JAK kinases over a panel of 38 additional kinases at 1 ?M. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-? levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.{48761} Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1?, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • trans-N-methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
  • Correlated keywords
    • JAK Janus-associated kinase JAKi PF03394197 JAK1 JAK2 JAK3 JAK4 PF-3394197 PF3394197 APOQUEL
  • Product Overview:
    Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).{30396} It is selective for JAK kinases over a panel of 38 additional kinases at 1 ?M. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-? levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.{48761} Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1?, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.

We also advise you